Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. Present-day treatments have not shown real improvements in reducing the high mortality rate and the short survival of the disease. The average survival is less than 5% after 5 years. New innovative treatments are necessary to curtail the situation. The very dense pancreatic cancer stroma is a barrier that impedes the access of chemotherapeutic drugs and at the same time establishes a pro-proliferative symbiosis with the tumor, thus targeting the stroma has been suggested by many authors. No ideal drug or drug combination for this targeting has been found as yet. With this goal in mind, here we have explored a different complementary treatment based on abundant previous publications on repurposed drugs. The cell surface protein CD44 is the main receptor for hyaluronan binding. Many malignant tumors show over-expression/over-activity of both. This is particularly significant in pancreatic cancer. The independent inhibition of hyaluronan-producing cells, hyaluronan synthesis, and/or CD44 expression, has been found to decrease the tumor cell's proliferation, motility, invasion, and metastatic abilities. Targeting the hyaluronan-CD44 pathway seems to have been bypassed by conventional mainstream oncological practice. There are existing drugs that decrease the activity/expression of hyaluronan and CD44: 4-methylumbelliferone and bromelain respectively. Some drugs inhibit hyaluronan-producing cells such as pirfenidone. The association of these three drugs has never been tested either in the laboratory or in the clinical setting. We present a hypothesis, sustained by hard experimental evidence, suggesting that the simultaneous use of these nontoxic drugs can achieve synergistic or added effects in reducing invasion and metastatic potential, in PDAC. A non-toxic, low-cost scheme for inhibiting this pathway may offer an additional weapon for treating pancreatic cancer.

Changes in DNA integrity and gene expression in ovarian follicular cells of lipopolysaccharide-treated female mice

BACKGROUND

Lipopolysaccharide (LPS), the endotoxin of gram-negative bacteria, can impair female reproductive function. However, there is a little information about genotoxic stress in ovarian follicular cells as well as about the changes in oocyte developmental potential under endotoxemia. So the aim of our study was to investigate in vitro oocyte maturation, the DNA damage and expression of some developmental competence-related genes in follicular cells of mice treated with LPS.

METHODS

LPS (3mg/kg) was intraperitoneally injected into the mice for 24h, and in vitro maturation of mouse oocyte was determined. The expression levels of genes in cumulus cells were detected by reverse transcriptase polymerase chain reaction. DNA damage in granulosa cells was assessed by the alkaline comet assay.

RESULTS

LPS injection caused an impairment of oocyte maturation in vitro: the percentage of oocytes reaching metaphase I and metaphase II decreased markedly compared to vehicle control mice. At the same time we observed strong DNA damage in granulosa cells of LPS-treated animals. The endotoxemia resulted in significantly reduced mRNA expression levels for hyaluronan synthase 2 (HAS2), cyclooxygenase 2 (COX2) and Gremlin-1 (GREM1) genes compared with control.

CONCLUSIONS

Our results obtained in a mouse model of endotoxin-induced female reproductive dysfunction suggest that LPS may affect oocyte quality through the induction of DNA damage and decreasing the cumulus expression of genes associated with cumulus expansion and oocyte maturation, such as HAS2, COX2 and GREM1.